GEMCITABINE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H11F2N3O4.ClH
Molecular Weight	299.6594
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1cn([C@@]2([H])C([C@@]([H])([C@@]([H])(CO)O2)O)(F)F)c(nc1=N)O.Cl

InChI

InChIKey=OKKDEIYWILRZIA-OSZBKLCCSA-N

InChI=1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C9H11F2N3O4
Molecular Weight	263.1985
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.4609
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800025123 | https://www.ncbi.nlm.nih.gov/pubmed/20066470 | https://www.ncbi.nlm.nih.gov/pubmed/22002019http://www.drugbank.ca/drugs/DB00441
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s075lbl.pdf

Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. Gemcitabine inhibits thymidylate synthetase, leading to inhibition of DNA synthesis and cell death. Gemcitabine is a prodrug so activity occurs as a result of intracellular conversion to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate by deoxycitidine kinase. Gemcitabine diphosphate also inhibits ribonucleotide reductase, the enzyme responsible for catalyzing synthesis of deoxynucleoside triphosphates required for DNA synthesis. Finally, Gemcitabine triphosphate (diflurorodeoxycytidine triphosphate) competes with endogenous deoxynucleoside triphosphates for incorporation into DNA. Gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; metastatic ovarian cancer; inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer; and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
DNA replication 12 Target ID: map03030 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7481842 \| https://www.ncbi.nlm.nih.gov/pubmed/22002019	Inhibitor 7728
Ribonucleoside-diphosphate reductase M1 chain 5 Target ID: CHEMBL1830 Sources: http://www.drugbank.ca/drugs/DB00441	Inhibitor 7728
Target ID: DNA Sources: http://www.drugbank.ca/drugs/DB00441	Inhibitor 7728
T-24 3 Target ID: CHEMBL614774 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25833690	Inhibitor 7728	3.0 nM [IC50]
CAKI-1 4 Target ID: CHEMBL614067 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25833690	Inhibitor 7728	30.0 nM [IC50]
PANC-1 6 Target ID: CHEMBL614139 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25517919	Inhibitor 7728	10.0 nM [IC50]
MIA PaCa-2 3 Target ID: CHEMBL614725 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25517919	Inhibitor 7728	7.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Pancreatic cancer 92 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25278310	Primary	Phase II 1101	Unknown Approved Use Unknown
Non-small cell lung cancer 195 Sources: https://clinicaltrials.gov/ct2/show/NCT01641575	Primary	Phase I 409	Unknown Approved Use Unknown
Advanced ovarian cancer 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s075lbl.pdf	Primary	Approved 8043	Gemzar Approved Use Gemzar is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. • in combination with cisplatin for the treatment of non-small cell lung cancer. • as a single agent for the treatment of pancreatic cancer. Launch Date 8.3203201E11
Metastatic breast cancer 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s075lbl.pdf	Primary	Approved 8043	Gemzar Approved Use Gemzar is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. • in combination with cisplatin for the treatment of non-small cell lung cancer. • as a single agent for the treatment of pancreatic cancer. Launch Date 8.3203201E11
Pancreatic cancer 92 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s075lbl.pdf	Primary	Approved 8043	Gemzar Approved Use Gemzar is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. • in combination with cisplatin for the treatment of non-small cell lung cancer. • as a single agent for the treatment of pancreatic cancer. Launch Date 8.3203201E11
Non-small cell lung cancer 195 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s075lbl.pdf	Primary	Approved 8043	Gemzar Approved Use Gemzar is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. • in combination with cisplatin for the treatment of non-small cell lung cancer. • as a single agent for the treatment of pancreatic cancer. Launch Date 8.3203201E11

C_max

Value	Dose	Analyte	Population
229 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122	75 mg/m² 1 times / week multiple, intravenous dose: 75 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	GEMCITABINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
263.6 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122	135 mg/m² 1 times / week multiple, intravenous dose: 135 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	GEMCITABINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
292.5 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122	180 mg/m² 1 times / week multiple, intravenous dose: 180 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	GEMCITABINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
3526.4 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122	75 mg/m² 1 times / week multiple, intravenous dose: 75 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	GEMCITABINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4818.5 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122	135 mg/m² 1 times / week multiple, intravenous dose: 135 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	GEMCITABINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4863.4 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122	180 mg/m² 1 times / week multiple, intravenous dose: 180 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	GEMCITABINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
5700 mg/m2 1 times / 2 weeks multiple, intravenous MTD Dose: 5700 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 5700 mg/m2, 1 times / 2 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf https://pubmed.ncbi.nlm.nih.gov/17434832	unhealthy, 55 years (range: 34-71 years) n = 4 Health Status: unhealthy Age Group: 55 years (range: 34-71 years) Sex: M+F Population Size: 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf https://pubmed.ncbi.nlm.nih.gov/17434832	Other AEs: Myelosuppression, Paresthesia... Other AEs: Myelosuppression Paresthesia Rash (severe) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf https://pubmed.ncbi.nlm.nih.gov/17434832
2200 mg/m2 3 times / 4 weeks multiple, intravenous MTD Dose: 2200 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 2200 mg/m2, 3 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/8996158	unhealthy, 58 years (range: 40-77 years) n = 6 Health Status: unhealthy Condition: Non-Small-Cell Lung Cancer Age Group: 58 years (range: 40-77 years) Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/8996158	Other AEs: Neutropenia, AST increased... Other AEs: Neutropenia (grade 2, 1 patient) AST increased (grade 2, 1 patient) ALT increased (grade 2, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/8996158
2800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 2800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 2800 mg/m2, 3 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/8996158	unhealthy, 58 years (range: 40-77 years) n = 5 Health Status: unhealthy Condition: Non-Small-Cell Lung Cancer Age Group: 58 years (range: 40-77 years) Sex: M+F Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/8996158	DLT: Hepatotoxicity, Neutropenic infection... Dose limiting toxicities: Hepatotoxicity (grade 3, 2 patients) Neutropenic infection (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/8996158
1000 mg/m2 3 times / 4 weeks multiple, intravenous Recommended Dose: 1000 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 3 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/30397477	unhealthy, 74 years n = 1 Health Status: unhealthy Age Group: 74 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/30397477	Disc. AE: Necrosis skin... AEs leading to discontinuation/dose reduction: Necrosis skin (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/30397477
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf	unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf	Disc. AE: Myocardial infarction, Cerebrovascular accident... AEs leading to discontinuation/dose reduction: Myocardial infarction (2%) Cerebrovascular accident (2%) Arrhythmia (2%) Hypertension (2%) Anemia (<1%) Thrombocytopenia (<1%) Hepatic dysfunction NOS (<1%) Kidney dysfunction (<1%) Nausea (<1%) Vomiting (<1%) Fever (<1%) Rash (<1%) Dyspnea (<1%) Hemorrhage (<1%) Infection (<1%) Stomatitis (<1%) Somnolence (<1%) Flu syndrome (<1%) Edema (<1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	TK2 4 hCNT1 3 hCNT2 3 hCNT3 3 MRP5 39

Drug as victim

Target	Modality	Activity
MRP5 39	substrate 3113 Sources: https://www.nature.com/articles/6601011/ Page: -	yes
TK2 4	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0923753419381785 Page: -	yes
hCNT1 3	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0923753419381785 Page: -	yes
hCNT2 3	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0923753419381785 Page: -	yes
hCNT3 3	substrate 3113 Sources: https://www.sciencedirect.com/science/article/pii/S0923753419381785 Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:175901	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:175901
ChemicalBook	CB4438054	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4438054
MolPort	MolPort-003-987-478	https://www.molport.com/shop/molecule-link/MolPort-003-987-478
Selleck Chemicals	Gemcitabine(Gemzar)	http://www.selleckchem.com/products/Gemcitabine(Gemzar).html
ZINC	ZINC000018279854	http://zinc15.docking.org/substances/ZINC000018279854

PubMed

Title	Date	PubMed
Acute myocardial infarction following gemcitabine therapy--a case report.	1999 Dec	10609769
Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas.	1999 Dec	10569619
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.	1999 Nov	10550159
Severe non-haematological toxicity after treatment with gemcitabine.	1999 Nov	10541971
Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines.	2000	11138460
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.	2000 Aug	10955861
Paclitaxel-induced stomal neuropathy: a unique cause of pain in a patient with ileal conduit.	2000 Dec 20	11113764
A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.	2000 Jan	10690391
Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1.	2000 Jan-Feb	10772724
Malignant pleural mesothelioma.	2001	11224994
Treatment of extensive stage small cell lung cancer.	2001	11224990
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.	2001	11224988
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer.	2001	11182002
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.	2001 Apr	11259616
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.	2001 Apr 20	11291097
[Palliative therapy of pancreatic adenocarcinoma].	2001 Feb	11253511
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.	2001 Feb	11252890
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.	2001 Feb	11252889
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.	2001 Feb	11252888
Treatment of advanced breast cancer with gemcitabine and vinorelbine.	2001 Feb	11252883
Chemotherapy agents in transitional cell carcinoma: the old and the new.	2001 Feb	11246730
Effects of gemcitabine on cisplatin-induced nephrotoxicity in rats: schedule-dependent study.	2001 Feb	11243722
The clinical implications of gemcitabine radiosensitization.	2001 Feb	11234872
Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.	2001 Feb	11172670
Gemcitabine and cisplatin for advanced, metastatic bladder cancer.	2001 Feb 15	11181690
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.	2001 Feb 15	11181671
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.	2001 Feb-Mar	11165412
Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings.	2001 Jan	11295355
Phase I trial of gemcitabine in patients with advanced pancreatic cancer.	2001 Jan	11256843
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.	2001 Jan	11249055
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.	2001 Jan	11249034
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.	2001 Jan	11243375
Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.	2001 Jan	11221019
Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.	2001 Jan	11221017
Anticancer drug-induced kidney disorders.	2001 Jan	11219485
Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer.	2001 Jan	11173544
Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study.	2001 Jan 15	11180090
Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer.	2001 Mar	11301847
Triplet combination chemotherapy and targeted therapy regimens.	2001 Mar	11301845
Gemcitabine in combination with new platinum compounds: an update.	2001 Mar	11301843
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients.	2001 Mar	11290868
[A case of primary malignant hemangiopericytoma of the lung with marked response to combination chemotherapy with cisplatin, ifosfamide and gemcitabine].	2001 Mar	11265407
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.	2001 Mar	11258776
Optimizing chemoradiation therapy approaches to unresectable stage III non--small cell lung cancer.	2001 Mar	11224708
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.	2001 Mar 1	11172947
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.	2001 Mar 15	11251001
Cotton-wool spots associated with pancreatic carcinoma.	2001 Mar 26	11309222
Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance.	2001 Mar 30	11133996
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.	2011 Jun	20066470
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.	2012 Oct	22002019

Patents

Sample Use Guides

In Vivo Use Guide

In phase 2 study against pancreatic cancer, the drug was administered intravenously at 1250 mg/m2/d on day 1, 8 and 15 of each 4-week cycle.

Route of Administration: Intravenous

In Vitro Use Guide

The in vitro experiments were performed in cell lines of leukemia and solid tumor origin, both sensitive and resistant to gemcitabine. All populations were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO2. Sensitivity to drugs was defined by the concentration of the drug causing a growth inhibition of 50% (IC50) after 72 h drug exposure of the cells. The cells were plated in 24-well plates in different densities, depending on their doubling times, to enable log-linear growth for 72 h. Drugs were added directly after plating the cells. Final concentrations of the drugs in the wells ranged from 2.10−10 to 10−3 M.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 20:56:25 UTC 2021` Edited by `admin` on `Fri Jun 25 20:56:25 UTC 2021`
Record UNII	U347PV74IL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GEMCITABINE HYDROCHLORIDE

Official Name

English

GEMCITABINE HYDROCHLORIDE [MI]

Common Name

English

GEMCITABINE HYDROCHLORIDE [VANDF]

Common Name

English

GEMCITABINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

GEMCITABINE HYDROCHLORIDE [WHO-DD]

Common Name

English

INFUGEM

Brand Name

English

4-AMINO-1-((2R,4R,5R)-3,3-DIFLUORO-4-HYDROXY-5-(HYDROXYMETHYL)OXOLAN-2-YL)PYRIMIDIN-2-ONE HYDROCHLORIDE

Systematic Name

English

GEMCITABINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

GEMCITABINE HYDROCHLORIDE [USP-RS]

Common Name

English

GEMCITABINE HYDROCHLORIDE [MART.]

Common Name

English

GEMCITABINE HYDROCHLORIDE [JAN]

Common Name

English

LY-188011 HYDROCHLORIDE

Code

English

GEMZAR

Brand Name

English

CYTIDINE, 2'-DEOXY-2',2'-DIFLUORO-, MONOHYDROCHLORIDE

Common Name

English

2'-DEOXY-2',2'-DIFLUOROCYTIDINE MONOHYDROCHLORIDE (.BETA.-ISOMER)

Common Name

English

GEMCITABINE HYDROCHLORIDE [USAN]

Common Name

English

LY188011 HYDROCHLORIDE

Code

English

GEMCITABINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

GEMCITABINE HCL

Common Name

English

GEMCITABINE (AS HYDROCHLORIDE)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1557